Standard BioTools Inc. Sales Revenue, Goods, Gross (Deprecated 2018-01-31)
Standard BioTools Inc. (LAB) reported Sales Revenue, Goods, Gross (Deprecated 2018-01-31) of $84.40 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsGross · last filed 2018-03-08
- Standard BioTools Inc. sales revenue, goods, gross (deprecated 2018-01-31) for fiscal 2017 was $84.40M, a 5.17% decline from fiscal 2016.
- Standard BioTools Inc. sales revenue, goods, gross (deprecated 2018-01-31) for fiscal 2016 was $89.00M, a 12.86% decline from fiscal 2015.
- Standard BioTools Inc. sales revenue, goods, gross (deprecated 2018-01-31) for fiscal 2015 was $102.14M, a 4.61% decline from fiscal 2014.
- Standard BioTools Inc. sales revenue, goods, gross (deprecated 2018-01-31) for fiscal 2014 was $107.07M, a 64.25% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Gross (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-31 | $84.40M 10-K · filed 2018-03-08 |
| 2016-12-31 | $89.00M 10-K · filed 2018-03-08 |
| 2015-12-31 | $102.14M 10-K · filed 2018-03-08 |
| 2014-12-31 | $107.07M 10-K · filed 2017-03-03 |
| 2013-12-31 | $65.19M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |